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Abstract Ceramide, the precursor of all complex sphin-
golipids, is a potent signaling molecule that mediates key
events of cellular pathophysiology. In the nervous system,
the sphingolipid metabolism has an important impact.
Neurons are polarized cells and their normal functions,
such as neuronal connectivity and synaptic transmission,
rely on selective trafficking of molecules across plasma
membrane. Sphingolipids are abundant on neural cellular
membranes and represent potent regulators of brain
homeostasis. Ceramide intracellular levels are fine-tuned
and alteration of the sphingolipid–ceramide profile con-
tributes to the development of age-related, neurological
and neuroinflammatory diseases. The purpose of this
review is to guide the reader towards a better understanding
of the sphingolipid–ceramide pathway system. First, cera-
mide biology is presented including structure, physical
properties and metabolism. Second, we describe the func-
tion of ceramide as a lipid second messenger in cell
physiology. Finally, we highlight the relevance of sphin-
golipids and ceramide in the progression of different
neurodegenerative diseases.
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Introduction
Ceramides are a family of lipid molecules that consist of
sphingoid long-chain base linked to an acyl chain via an
amide bond. Ceramides differ from each other by length,
hydroxylation, and saturation of both the sphingoid base
and fatty acid moieties.
Sphingoid bases are of three general chemical types:
sphingosine, dihydrosphingosine (commonly known as
‘‘sphinganine’’, as it will be addressed in this review) and
phytosphingosine. Based on the nature of the sphingoid
base backbone, we can distinguish three main subgroups in
the ceramide family: the compound named ceramide con-
tains sphingosine, which has a trans-double bond at the
C4–5 position in the sphingoid base backbone; dihydro-
ceramide, the inactive precursor of ceramide, contains
sphinganine, which presents a saturated sphingoid back-
bone devoid of the 4,5-trans-double bond; phytoceramide,
the yeast counterpart of the mammalian ceramide, contains
phytosphingosine, which has a hydroxyl group at the C4
position [1] (Fig. 1).
The fatty acid components of ceramides vary widely in
composition, but they are typically long. Their acyl chain
lengths range from 14 to 26 carbon atoms (or greater),
although the most common fatty acids are palmitic (C16:0)
and stearic (C18:0) non-hydroxy fatty acids. The fatty acids
are commonly saturated or mono-unsaturated. a-Hydrox-
ylated fatty acids (a hydroxyl group at the C-2 position)
and x-hydroxy fatty acid (a hydroxyl group on the terminal
C atom) are often present as well [2].
Activation of ceramide
Small changes in the molecular structure of ceramide moiety
can regulate its biological function. Dihydroceramide is an
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early intermediate in the de novo ceramide biosynthesis.
Considered the innocuous precursor of ceramide, dihydro-
ceramide differs from ceramide only by reduction of the
C4–5 trans-double bond in the sphingoid backbone inhib-
iting [3] or reducing its biological activity [4] when
compared with ceramide moiety. The introduction of a







synthesized by the transfer of
the phosphorylcholine moiety to
the C-1 hydroxyl group of
ceramides, is the only cell
membrane phospholipid not
derived from glycerol.
Alternatively, modification of a
ceramide by addition of one or
more sugars directly connected





have a single monosaccharide
(galactose or glucose) as polar
head group; sulfatides are the
sulfuric acid esters of
galactocerebrosides. Addition of
a galactose to glucosylceramide
gives rise to lactosylceramide,
precursor of globo-, ganglio-
and lactosides. Globosides
contain multiple sugar moieties.
Ganglio- and lactosides have a
complex oligosaccharide core
structures with one or more
sialic acids in the polar head
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trans-double bond between C4 and C5 results in the bio-
active molecule of ceramide. This reaction is catalyzed by
the enzyme (dihydro)-ceramide desaturase, which is local-
ized in the cytosolic leaflet of the endoplasmic reticulum
(ER) membrane [5, 6]. In this way, cells can fine-tune the
amount of biologically active ceramide. The presence of the
double bond in the sphingosine chain determines the tilt of
ceramides in the membrane and enables the lipid to interact
with enzymes such as hydrolases and phosphatases [7].
Moreover, unsaturation in the sphingoid backbone
augments intramolecular hydration/hydrogen bonding in
the polar region. This may allow the close packing of the
ceramide molecules, which exhibit a tighter intramolecular
interaction than comparable lipids [8–10]. This higher
packing density of ceramides within the lipid bilayer
affects the physical properties of membranes [11].
Short-chain ceramide
Synthetic short-chain ceramides (N-acyl chains of 2 to 8
carbon atoms) are commonly used to mimic the mecha-
nisms of action of naturally occurring long-chain
ceramides, which are highly hydrophobic compounds.
Short-chain ceramides are water soluble and membrane-
permeable and can be easily used as experimental tools
within living cells [12–16]. Small amounts of C2-ceramide
are normal components in brain (10 pmol/g) and liver
(25 pmol/g) [17] although the metabolic origin and phys-
iological activity of this short ceramide are uncertain.
NMR characterization of C-2 and C-18 ceramides
showed that the conformation of the polar region of the two
molecules is the same [9]. Since the interaction between
ceramides and their ligand molecules probably occurs
through the polar head, the maintenance of the headgroup
conformation irrespective of N-acyl chain length is enough
for C-2 ceramides to reproduce most of the long-chain
ceramides signaling effects. However, the length of the
fatty acyl chain modifies significantly the biophysical
properties of the ceramide moieties [18] and in some
reports long- and short-chain ceramides have been found to
have different biological effects [19, 20].
The major difference between short and long ceramides
is in the geometrical shapes they adopt at the membrane
level that consequentially gives rise to different behaviors.
The hydrophobic portion of C-2 is smaller than the polar
headgroup. Therefore, C-2 has a shape that favors a
positive curvature in lipid monolayer [21]. Long-chain
ceramides are cone shaped molecules with opposite geo-
metrical properties, which induce a negative curvature of
the two halves of the bilayer towards the aqueous milieu,
leading to membrane trafficking via vesiculation and
fusion [22, 23]. Moreover, long-chain ceramides increase
the order of the acyl chains in the bilayers, thus decreasing
fluidity and stabilizing the membrane [24–26]. Conversely,
short-chain ceramides perturb the structural order of the
lipid bilayer. Long-chain ceramides are immiscible with
phospholipids, while short-chain ceramides mix much
better and are therefore able to spontaneously overcome
membrane barriers [27]. Once inside the cell since they
possess the appropriate stereochemistry, short ceramides
might bind target proteins normally inaccessible for
the longer species. On the contrary, naturally occurring long-
ceramides are eminently hydrophobic even compared to
other lipid species and as a consequence their concentrations
in the cytosol are extremely low. This hydrophobicity of
ceramides justifies the need for a ceramide transfer protein
(CERT) in cells [28]. CERT localizes inside the cell and
modulation of its activity may result in significant changes in
ceramide levels [62]. Therefore, since short-chain ceramides
behave as soluble amphiphiles [29], they are suspected to
have cellular effects that cannot be extrapolated to natural
ceramide species (mainly insoluble amphiphiles) and their
use might lead to confusion on the role of ceramide in cellular
signaling.
Ceramides as precursors of sphingolipids
Free ceramides are molecules known to exert a wide range
of biological functions in many of the most critical cellular
events, including growth, differentiation, apoptosis and
oncogenesis. Ceramides are the core structure of a class of
complex lipid called sphingolipids, ubiquitous components
of eukaryotic cell membranes [30]. Sphingolipids were
initially described in brain tissue in the second half of the
19th century [31]. The name sphingolipids denotes their
enigmatic (namely sphinx-like) nature that, despite intense
research, still remains unclear. Sphingolipids have long
been regarded as inactive and stable structural compo-
nents of the membrane; however they are now well
recognized to be biologically active in processes of cellular
biology.
Sphingolipids are very heterogeneous and are classified
depending on their structural combinations in long-chain
(sphingoid) bases, amide-linked fatty acids [32] and hun-
dreds of headgroup variants [33].
Sphingolipids are generated by attachment of different
polar headgroups at the primary alcohol group (C1–OH) of
a ceramide molecule. Depending on the type of polar
group, two major classes are defined: phosphosphingolipids
and glycosphingolipids (GSLs) (Fig. 1). The typical
phosphosphingolipid in mammalian cells is sphingomyelin
(SM), synthesized by the transfer of the phosphorylcholine
moiety (from phosphatidylcholine) to the C1–OH of
ceramides.
Alternatively, modification of a ceramide by addition of
one or more sugars yields complex GSLs. As a result of the
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great heterogeneity in the glycan moiety, among GSLs
much variation exists. When a single monosaccharide is
present, the GSL is referred to as a cerebroside (also known
as monoglycosylceramides). Usually glucose or galactoses
are attached directly to the ceramide portion of the molecule,
resulting in glucosylceramide (GlcCer; glucocerebroside)
and galactosylceramide (galactocerebroside), respectively.
The sulfuric acid esters of galactosylceramide are the sul-
fatides. Galactosylceramide and sulfatide are highly
enriched in oligodendrocytes and myelin-forming cells
compared to other membranes [34]. By contrast GlcCer
is not normally found in neuronal cell membranes. Addi-
tionally, a galactose can be transferred by the enzyme
lactosylceramide synthase to GlcCer to form lactosylcera-
mide (LacCer) [35, 36], which plays a pivotal role as a
precursor for the synthesis of complex GSLs [37]. In fact, the
common LacCer structure is then elongated by different
glycosyltransferases, thereby defining the classes of GSLs
that are identified as ganglio-, globo-, lacto- and (neo)-lacto-
subtypes according to their specific saccharide core
structures.
Globosides represent cerebrosides that contain addi-
tional carbohydrates predominantly galactose, glucose or
N-acetylgalactosamine (GalNAc). Gangliosides are very
similar to globosides except that they also contain one or
more sialic acid residues on their carbohydrate chains.
Gangliosides comprise approximately 5 % of brain lipids
and are mainly present in astroglia, followed by neurons
and oligodendrocytes. Lacto and (neo)-lacto-series are
GSLs classified on the basis of the core oligosaccharide
structures present in their molecules and catalyzed by the
transfer of N-acetylglucosamine (GlcNAc) onto LacCer
[35]. Polar carbohydrate chains of GSLs extend toward the
extracellular milieu, forming specific patterns on the sur-
face of cells, contributing to cell recognition during
differentiation, development and immune reaction [38].
These different types of sphingolipids can be converted
back to ceramide by the removal of the polar headgroup by
specific enzymes.
Ceramide generation
Ceramides can be produced in cells either via the de novo
synthesis or via hydrolysis of complex sphingolipids [39].
The activation of different catabolic enzymes yields cera-
mide within a few minutes whereas the de novo synthesis
produces ceramide in several hours [40]. Different extra-
and intra-cellular stimuli dictate the pathway used for
ceramide generation resulting in distinct subcellular
localization of ceramide and different biochemical and
cellular responses.
De novo synthesis of ceramide takes place in the ER
In animal cells, ceramide is de novo-synthesized on the
cytoplasmic face of the smooth endoplasmic reticulum
(ER) [5, 41] and in mitochondria [42, 43].
The de novo synthesis of ceramides in eukaryotes begins
with the condensation of serine and palmitoyl-CoA to form
3-ketosphinganine, through the action of serine palmitoyl
transferase (SPT) (Fig. 2). This enzyme is composed of
two subunits: Lcb1 and Lcb2. Mutations in the human
Lcb1 gene underlie hereditary autonomous neuropathy, a
neurodegenerative disorder of the peripheral nervous sys-
tem [44].
Subsequently, 3-keto-sphinganine is reduced to the
sphingoid base sphinganine, which is subsequently N-acyl-
ated by (dihydro)-ceramide synthase (CerS) to form
dihydroceramide. The enzyme (dihydro)-ceramide desatur-
ase introduces the double bond to the position C4 to form
mammalian type ceramides [6, 45].
CerS represents a key enzyme in the pathway for de
novo sphingolipid biosynthesis. Interestingly, these highly
conserved transmembrane proteins are also known as
human homologues of yeast longevity assurance gene
(LASS1).
Six different CerSs (CerS1–6) have been identified in
vertebrates and plants [46], whereas most of the other
enzymes involved in sphingolipids metabolism exist in
only one or two isoforms [46]. Each CerS regulates the de
novo synthesis of endogenous ceramides with a high
degree of fatty acid specificity. In line with the presence of
multiple CerSs, ceramides occur with a broad fatty acids
length distribution inside the cell. Although some CerSs are
ubiquitously expressed, other isoforms present a very
specific distribution among tissues, according to the need
of each tissue for specific ceramide species [47, 48]. CerS1
specifically generates C18 ceramide and is highly expres-
sed in the brain and skeletal muscles but is almost
undetectable in other tissues. CerS2 mainly generates
C20–26 ceramides and has been found to have the highest
expression of all CerSs in oligodendrocytes and Schwann
cells especially during myelination. The selectivity of dif-
ferent CerS isoforms to synthesize different ceramide
species is important since ceramides with specific acyl
chain lengths might mediate different responses within
cells [46]. Fumonisins are toxic mycotoxins with a very
similar structure to sphingosine or sphinganine, which is a
substrate for CerS. Since these fungal metabolites are able
to inhibit CerS reaction, they are extensively used to study
the role of ceramide generated through the de novo path-
way in the ER [49]. On the contrary, the mitochondrial
CerS is not affected by fumonisins, suggesting that its
activity is distinct from the ER resident enzyme [42, 43].
184 C. Mencarelli, P. Martinez–Martinez
123
Neo-synthesized ceramides subsequently traffic from the
luminal face of the ER to the Golgi compartment where
different polar heads are incorporated into the ceramide
molecule to form complex sphingolipids [50].
Ceramide transport from ER to the Golgi
The high hydrophobicity and low polarity of ceramide
moiety limit free ceramide to circulate inside the cell or
more generally in solution. This may explain the occur-
rence of several isoenzymes of ceramide biosynthesis at
different subcellular sites and supports the view that the
site of ceramide formation might determine its function.
On the other hand, the cell needs to transport ceramide
from the ER to the Golgi compartment for the synthesis of
GSLs and SM. Ceramides destined for conversion to GSLs
appear to reach the Golgi only via the classical vesicular
route [28]. The step-wise addition of sugar groups to
ceramides is catalyzed by membrane bound glycosyl-
transferases and it is restricted to the ER-Golgi complex
[51]. The synthesis of most GSLs begins with glucosyla-
tion of ceramide to form GlcCer, at the cytosolic surface of
the Golgi [52]. The direction in which GlcCer is trafficked
is controversial. GlcCer normally localizes to trans-Golgi
and trans-Golgi network, whereas it remains in the cis-
Golgi on the knockdown of FAPP2. Two inhibitors of
intra-Golgi membrane trafficking did not affect the syn-
thesis of GSLs. These observations suggest that GlcCer is
transported from the cis-side of Golgi to the trans side by
FAPP2 in a nonvesicular manner [53]. On the other hand, it
has been suggested that GlcCer synthesized at the Golgi is
retrogradely transported to the ER, where it is translocated
to the lumen, and then transported to the Golgi again [54]
for the subsequent synthesis of LacCer and more complex
GSLs [55].
Ceramides destined for the formation of SM reach the
Golgi carried by CERT in a non-vesicular manner [28, 56–
58].
CERT mediates the transfer of ceramides containing
C14–C20 fatty acids but not longer-chain ceramides [59].
This correlates with the presence of a C14–20 acyl chain
SM in many tissues and cell lines whereas GSLs are
formed by longer ceramides. CERT, works as mediator of
sphingolipids homeostasis. Loss of functional CERT in
Drosophila affects plasma membrane fluidity and increases
oxidative stress [60] and CERT is critical for mitochondrial
and ER integrity [61]. Interestingly, CERT has an alter-
natively spliced isoform characterized by the presence of
an additional 26 amino acids domain, responsible for its
localization at the plasma membrane and consequent
secretion to the extracellular milieu, named CERTL or
Goodpasture antigen binding protein (GPBP) [62]. These
two isoforms are differentially expressed during develop-
ment. CERTL is more abundant at early stages of
embryonic maturation and its knockdown leads to severe
developmental deficit in muscle and brain because of
increased apoptosis [63]. As development progresses, the
initially very low levels of CERT, gradually increase. Both
isoforms can be detected in adult brain [64].
Other reports showed elevated CERTL expression levels
to be associated with several autoimmune disorder e.g.,
lupus erythematosus, multiple sclerosis, myasthenia gravis,
Fig. 2 Overview of the metabolic pathways involved in the
synthesis of endogenous ceramide. Ceramide can be formed by de
novo synthesis, by degradation of complex SLs or by re-acylation of
sphingoid long-chain bases (salvage pathway). The de novo pathway
involves several enzymatic steps. Through catabolic pathways
ceramide is generated by either hydrolysis of the membrane lipid
SM by the SMase enzymes or by lysosomal breakdown of complex
GSLs. Ceramide itself is degraded by ceramidase to regenerate
sphingoid bases. The sphingosine formed is then phosphorylated and
finally degraded to phosphoethanolamine and C16-fatty aldehyde by
the action of S1P lyase. A salvage pathway uses the enzyme ceramide
synthase to produce ceramide from sphingosine. Once generated,
ceramide can serve as a substrate for the synthesis of SM and GSLs or
be converted into various metabolites such as sphingosine or Cer1P
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Addison disease [65]. An efficient execution of apoptotic
signaling is important to inhibit inflammation and auto-
immune responses against intracellular antigens [66] and
modulation of CERT/CERTL levels has a direct influence
in ceramide levels and could be responsible for balancing
cell death during embryogenesis and under pathophysio-
logical condition.
Once delivered to the Golgi apparatus, ceramide spon-
taneously translocates from the cytosolic to the luminal
leaflet for SM synthesis. Formation of SM from ceramide is
catalyzed by sphingomyelin synthase (SMS) [67] that
transfers the phosphocholine headgroup from phosphati-
dylcholine onto ceramide yielding SM as a final product
and diacylglycerol (DAG) as a side product [68]. If cera-
mide is a key metabolic intermediate for sphingolipids with
an amide backbone, DAG is the precursor for glycerol-
derived phospholipids and, as well as ceramide, it plays
important roles in many signaling pathways. Whether the
DAG generated by SMS regulates cellular processes
remains unclear. SMS exists in two isoforms, SMS1, faces
the lumen of the cis/medial Golgi [69, 70] and it is
responsible for the de novo synthesis of SM [70]; SMS2,
which resides in the plasma membrane [68, 71], could
instead play a more specific role in signal transduction
events. In neural cells the de novo SM is mostly synthe-
sized at the plasma membrane and the production at the cis
medial Golgi is less prominent [72, 73]. This indicates that
the subcellular localization of SM formation is cell type
specific and that SMS activities may be involved in dif-
ferent biological processes.
Catabolic pathways for ceramide production
Beside the de novo pathway, significant contribution to
intracellular ceramide levels occur also through hydrolysis
of complex sphingolipids by activation of different
hydrolases [74] (Fig. 2).
Ceramides derived from SM catabolism require the
activation of sphingomyelinases (SMase) [75], specific
forms of phospholipase C, which hydrolyze the phosphodi-
ester bond of SM yielding water soluble phosphorylcholine
and ceramide [76]. Several SMases have been characterized
and classified by their pH optimum, subcellular distribution
and regulation. The best-studied of these SMases is the acid
sphingomyelinase (aSMase), which exhibits an optimal
enzymatic activity at pH 4.5–5 [77]. This lipase is localized
in lysosomes and is required for the turnover of cellular
membranes [78]. ASMase is deficient in patients with the
neurovisceral form (type A) of Niemann–Pick disease, with
consequent abnormal accumulation of SM in many tissues
of the body [79]. Besides this lysosomal/endosomal aSMase,
a secreted zinc-activated form of aSMase was first identified
in serum [80] and found to be secreted by many cell types
[81, 82]. These two aSMases are differentially glycosylated
and processed at the NH2-terminal (72) but they are products
of the same gene [81]. Neutral SMases (nSMase) are
membrane bound enzymes with an optimal activity at a
neutral pH. Several isoforms have been characterized.
NSMase 1 is localized in the membranes of the ER, [83, 84]
and it is ubiquitously expressed and highly enriched in
kidney [85]. NSMase 2 has a different domain structure than
nSMase 1 and is specifically highly expressed in brain [86,
87] [88]. A third nSMase (nSMase 3) is ubiquitously present
in all cell types and distributed mainly in the ER and Golgi
membrane [89]. NSMases are further classified as Mg2?/
Mn2? dependent or independent. An alkaline SMase exists
only in intestinal cells and it is activated by bile salts [90].
The function of these multiple isoforms is still elusive;
however their membrane localization has lead to speculation
that they may contribute to the modification of local
microdomains in the membrane organization during vesicle
formation, transport, and fusion [91, 92].
Salvage pathway
Ceramides can be generated by an alternative acyl-CoA-
dependent route (Fig. 2). This pathway relies upon the
reverse activity of the enzyme ceramidase (CDase), which
is called the ‘‘salvage pathway’’ since catabolic fragments
are recycled for biosynthetic purposes [93, 94]. As the
name suggests, CDase catalyses the hydrolysis of ceramide
to generate free sphingosine and fatty acid. Together with
ceramide production, CDase regulates also sphingosine
levels. In fact, it is important to note that whereas sphin-
ganine is generated by de novo sphingolipid biosynthesis
(Fig. 2), free sphingosine seems to be derived only via
turnover of complex sphingolipids, more specifically by
hydrolysis of ceramide [5]. The catabolism of ceramide
takes place in lysosomes from where sphingosine can be
released [95] in contrast to ceramide, which does not
appear to leave the lysosome [96]. Free sphingosine is
probably trapped at the ER-associated membranes where it
undergoes re-acylation (condensation with a fatty-acyl-
CoA) to again generate ceramide. This ‘‘reverse’’ activity is
carried out by the same CDase [96, 97].
As with SMase, different CDases have been identified
associated with different cellular compartments according
to the pH at which they achieve optimal activity (acid,
neutral and alkaline). Acid CDases (aCDase) are lysosomal
[98–100], whereas neutral/alkaline CDases (nCDase and
alCDase) have been purified from mitochondria [42, 101]
and nuclear membranes [102]. CDases have been isolated
from soluble fractions of rat brain [103], mouse liver and
human kidney. A purely alkaline CDase has been localized
to the Golgi apparatus and ER [104, 105]. This variability
in CDases subcellular localizations and distribution in
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tissues suggests that these enzymes may have diverse
functions in the biology of the cell.
N/a CDases have been shown to catalyze the reverse
reaction to generate ceramide from sphingosine and fatty
acids [97, 104, 106, 107] whereas the acid isoform resides
in lysosome. Mitochondria are also capable of generating
ceramide via the action of reverse CDase [42, 101, 108].
Sphingosine-1-phosphate and ceramide-1-phosphate
Phosphorylation/dephosphorylation reactions represent a
mechanism through which cells respond to specific chan-
ges: the phosphorylated state of a molecule often exhibits
effects that are diametrically different from those of the
unphosphorylated state. Besides being used to resynthesize
ceramide, sphingosine can be converted into sphingosine-
1-phosphate (SP1) via sphingosine kinase, an enzyme that
exists in the cytosol and ER [109, 110] (Fig. 2). The ter-
minal catabolism of sphingosine involves the action of SP1
lyase, which degrades the SP1 to form ethanolamine
phosphate and a fatty aldehyde [111]. Sphingosine is
associated with growth arrest [112] whereas its phosphor-
ylated form, SP1, is able to promote cell proliferation and
prevent programmed cell death [110] (for a review [113]).
Ceramide and S1P that exert effects of opposite nature
in their regulation of apoptosis, differentiation, prolifera-
tion and cell migration [114, 115]. The concentration of
ceramide and S1P is counter-balanced by enzymes that
convert one lipid to the other and their levels are believed
to balance between cell viability and cell death.
However, this is not the only way the cell can balance to
ensure tissue homeostasis. Ceramides can also be phos-
phorylated by the enzyme ceramide kinase (CERK) to form
ceramide-1-phosphate (Cer1P) [116–119]. As expected,
phosphorylation of ceramide in Cer1P allows a switch of
ceramide properties: comprehensive studies indicate that
Cer1P inhibits apoptosis and can induce cell survival [120–
122].
CERK was first observed in brain synaptic vesicles
[117] and found to be highly expressed in brain, heart,
skeletal muscles and liver [116]. It appears that at least two
different CERK isoforms exist in neural tissue, a calcium
dependent enzyme at the plasma membrane level and a
second cytosolic enzyme [123, 124]. The former enzyme
localizes at synaptic-vesicles suggesting a possible role for
CERK in neurotransmitter release [116, 117, 125].
CERK specifically utilizes ceramide transported to the
Golgi apparatus by CERT [126]. Stable downregulation of
CERT by RNA interference results in strong decrease in
Cer1P levels, suggesting that Cer1P formation mostly
relies on ceramide de novo synthesis [126]. Together with
CERK and Cer1P phosphatases, CERT could modulate an
appropriate balance between the intracellular levels of
ceramide and Cer1P. However it is important to mention
that short-term pharmacological inhibition of CERT
appears to slow down SM synthesis without decreasing
Cer1P synthesis [127], suggesting either an alternative
route for delivery of ceramide to CERK at the Golgi
complex or a process which is dependent on long-term
responses.
Maintenance of equilibrium between ceramide and
Cer1P seems to be crucial for cell and tissue homeostasis
and accumulation of one or the other results in metabolic
dysfunction and disease.
Recently, S1P was reported to function not only as an
intracellular but also as an extracellular mediator of cell
growth through endothelial-differentiation gene family
receptors [128]. Cer1P could exert similar functions at the
plasma membrane level. Further research is necessary to
study if ceramide could reach the plasma membrane
transported by CERTL allowing plasmatic membrane
CERK to form Cer1P.
Plasma membrane, not just a lipid bilayer
Structural organization of the membrane
The plasma membrane is the densest structure of eukary-
otic cells and it defines the outer limit of the cell with
its environment. Far from being a passive skin around a
cell, plasma membranes are highly dynamic structures with
a central role in a vast array of cellular processes
[129, 130].
Plasma membrane of eukaryotic cells comprises three
major classes of lipids: glycerophospholipids, sphingolipids
and sterols, principally cholesterol [131]. Glycerophos-
pholipids are the main building blocks of eukaryotic
membranes and differ from sphingolipids (ceramide based
lipids) in that they are built on a glycerol backbone [132].
Sphingolipid acyl chains are characteristically highly satu-
rated, this allows them to pack tightly in the lipid bilayer
and results in a liquid ordered phase with little opportunity
for lateral movement or diffusion. This characteristic makes
sphingolipids suitable to contribute heavily to the structure
of the outer leaflet [30]. Conversely, glycerophospholipids
are rich in unsaturated acyl chains that are typically kinked,
this means they pack loosely thus increasing the fluidity of
the lipid bilayer. The inner leaflet has a higher content of
unsaturated phospholipids. This lipid asymmetry in mem-
branes accounts for the greater fluidity of the inner layer
relative to the outer layer (Fig. 3).
Sphingolipids molar ratio relative to glycerophospho-
lipids and cholesterol varies within cell types. For instance,
GSLs are a very minor component in certain cell types such
as erythrocytes but they have been shown to be particularly
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abundant in neurons and oligodendrocytes where they
make up 30 % of total lipids in myelin sheets [133, 134].
Cholesterol affects the consistency of the plasma mem-
brane making the outer surface firm and decreasing its
permeability [135]. With its rigid ring structure, cholesterol
fills interstitial spaces between fatty acid chains of the
nearest phospholipids, restricting their movement. At the
same time cholesterol helps plasma membrane to maintain
its fluidity, separating the long saturated fatty acid tails of
phospholipids, avoiding their condensation. Despite the
significance of ceramide metabolism in the synthesis and
degradation of sphingolipids, ceramide content is normally
very low in cell membrane and increases in ceramide
concentration are highly localized and temporally regu-
lated. The occurrence of ceramide in the lipid bilayer
directly affects both the structural organization and the
dynamic properties of the cell membrane [11, 136].
Lipid raft
Many cellular processes such as endocytosis, exocytosis
and membrane budding involve changes in membrane
topology. While biological membranes are typically in a
fluid or liquid-disordered state at physiological tempera-
tures, combinatorial interactions between specific lipids
drives the formation of dense, liquid-ordered domains, or
‘lipid rafts’ within membranes [13, 130, 137, 138] (Fig. 3).
The characteristics of these microdomains differ from
those of the whole membrane. They are generally enriched
in lipids with saturated acyl chains, especially SM and
cholesterol which pack tightly within the lipid bilayer [139,
140]. These separated regions seem to exist as preformed
entities in the membrane of resting cells [141] and are
present in different parts of the lipid bilayer [142].
The straight saturated acyl chains of sphingolipids in
rafts are more extended than unsaturated chains of sur-
rounding phospholipids and as a result lipid rafts extend
1 nm beyond the phospholipids background [143]. The
isolation of biologically relevant lipid rafts is problematic.
In the past, highly saturated lipid rafts have been isolated
based on their detergent resistance [144]. More recently, it
has been shown that these detergent resistant membranes
(DRMs) are in fact a product of the extraction method and
do not reflect any specific membrane structure. Therefore,
it is important to recognize that rafts are not equivalent to
DRMs [145]. The majority of studies have investigated
lipid rafts mainly at the plasma membrane, due to their
accessibility from the outside of the cell [146–148].
However many intracellular organelles contain raft-like
domains [144, 149–152]. Membranes of the Golgi are rich
in cholesterol/SM [153–155] and it has been suggested that
rafts function in sorting of lipids and proteins in the
secretory and endocytic pathways. In particular, raft like
domains are thought to be abundant in the trans-Golgi [152,
156] and in late endosomes [151].
Lipid rafts are dynamic structures without any charac-
teristic morphology [157]: during the steady state, rafts
may be very small, nanometers in diameter [139, 158, 159]
Fig. 3 Schematic representation of lipid raft structures in a plasma
membrane. The phospholipid bilayer of cellular plasma membranes
contains many different lipid components such as glycerophospho-
lipids, sphingolipids and cholesterol. The compositions of the inner
and outer membrane leaflets are different. The cytoplasmic monolayer
is largely composed of aminophospholipids as phosphatidylserine (4)
and phosphatidylethanolamine (3). By contrast, the choline-contain-
ing lipids SM (6) and phosphatidylcholine (5) and a variety of
glycolipids (7, 8) are significant components of the exofacial leaflet of
plasma membranes [45]. SM (6) together with cholesterol and
different GSLs (7, 8), form highly organized microdomains called
lipid rafts on the plasma membrane. Since these microstructures are
formed by lipid species with long saturated acyl chains, rafts are rigid
platforms which float in the more fluid surrounding membrane that
consists of phospholipids with saturated (1) and unsaturated (2) fatty
acyl chains and less cholesterol. Lipids rafts are enriched in
glycosylphosphatidylinositol (GPI)-anchored proteins (8) at their
external surface and studded with transmembrane integral proteins
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but upon proper stimuli they can coalesce into large
domains making even micrometer-size rafts [159]. The
fundamental principle by which lipid rafts exert their
functions is a segregation or concentration of specific
membrane proteins and lipids to form distinct microdo-
mains [147] that represent specialized signaling organelles
within the plasma membrane [160]. These dynamic mem-
brane sites have been implicated in mechanisms of cell
polarity [161], membrane trafficking including endocytosis
[149, 162] and exocytosis [163–165] and in intracellular
signaling [160, 166–168].
Proteins which localize into lipid rafts often show post-
translational modifications with lipids such as glycosylpho-
sphatidylinositol (GPI)-anchors, palmitoylation, prenylation,
myristoylation, [169] or directly bind cholesterol or phos-
pholipids as caveolins [138, 170] and annexins [171],
respectively.
Ceramide-enriched platforms
As a highly hydrophobic second messenger, ceramide
presumably acts at the level of lipid rafts in transducing
external signal. Rafts are the primary site of action of the
enzyme SMase that releases ceramide from SM [172]
(Fig. 4). The tight interaction between SM and cholesterol
serves as the basis for raft formation. Ceramides, on the
other hand, mix poorly with cholesterol and have a
tendency to self associate and segregate into highly ordered
microdomains [13, 173]. The nature of ceramide has a
strong impact on membrane structure. In fact, long-chain
saturated ceramide molecules, are intermolecularly stabi-
lized by hydrogen bonding and van der Waal forces [25,
174] and form a liquid ordered domains that induce lateral
phase separation of fluid phospholipid bilayers into regions
of liquid-crystalline (fluid) phases. Moreover, the small
size of ceramide polar headgroup results in a low hydration
and allows ceramide molecules to pack tightly avoiding
any interference with surrounding lipids [175]. In fact it has
been shown that as little as 5 mol% ceramide is sufficient
to induce ceramide partitioning in the lipid bilayer and to
drive the fusion of small inactive rafts into one (or more)
larger active ceramide-enriched membrane platforms
[174].
Among lipids, DAG is structural similar to ceramide.
DAG is produced in the cell membrane by hydrolysis of
phosphatidylinositol 4,5-bisphosphate [176] and phospha-
tidylcholine [177]. Both are very minor components of
membrane being formed and removed rapidly at specific
locations in response to signaling. As well as ceramides,
DAGs also give rise to phenomena of lateral phase sepa-
ration in small domains within phospholipid bilayers. Both
ceramide [178] and DAG [179] have a small polar head
and a large hydrophobic region; they tend to bend the
bilayer and to facilitate the formation of non-bilayer (non-
Fig. 4 Scheme of lipid raft reorganization up in ceramide formation
by SMase activity. Hydrolysis of SM through the enzyme Smase
generates ceramide in the outer leaflet of the cell membrane. For its
biochemical features, ceramide mixes poorly with the other rafts
components and shows self-assembling capability in the membranous
environment forming large distinct ceramide-enriched membrane
platforms which serve to reorganize the cell membrane, resulting in
clustering of activated receptor molecules
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lamellar) phases which are important for cellular processes
such as pore formation, vesicle fusion and budding, as well
as membrane protein function. Also, both lipids act as
second messengers that play important roles in many sig-
naling pathways. DAG is able to induce structural changes
in membrane, more efficiently than ceramide, requiring as
little as 2 mol% [180]. This difference in efficiency is
likely due to the different physical properties of these
lipids. It is though that the different proficiencies of cera-
mide and DAG for induction of membrane structural
change through transient destabilization of the lamellar
structures provide opportunity for fine control of membrane
properties.
The ceramide-enriched membrane platforms serve as
clustering components to achieve a critical density of
receptors involved in signaling. In fact, rafts are too small
to engage in membrane processes [160, 181]. This high
density of receptors seems to be required for effective
transmission of the signal into cells. For example, CD95
signaling is amplified a hundred-fold by the formation of
ceramide-enriched membrane platforms [182].
The neuronal plasma membrane is particularly enri-
ched in lipid rafts [183]. More than 1 % of total brain
protein is recovered in a lipid raft fraction, whereas less
than 0.1 % of total protein is associated with lipid raft
isolated from non neuronal tissues [184]. In cultured
neurons, lipid rafts are distributed throughout the cell
surface including the soma and dendrites. As well as
across cell types, lipid and protein raft composition dif-
fers according to neuronal developmental stage. Mature
neuron lipid raft content is higher than that of immature
neurons and astrocytes. [185]. Synaptic proteins such as
synaptophysin or synaptotagmin localize in lipid rafts
[186, 187] and lipid rafts are critical for maintaining the
stability of synapses and dendritic spines [188]. Neuro-
transmitter signaling seems to occur through a clustering
of receptors and receptor-activated signaling molecules
within lipid rafts. Several lipid raft associated neuro-
transmitter receptors have been isolated from brain
tissues, examples include: nicotinic acetylcholine recep-
tors [189], gamma aminobutyric acid type B receptors
[190], a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid receptor and N-methyl-D-aspartate receptors [188,
191, 192]. Aberrant organization of SM and cholesterol
in rafts has been linked to loss of synapses and changes
in nerve conduction [188]. Depletion of sphingolipids or
cholesterol leads to gradual loss of inhibitory and excit-
atory synapses and dendritic spines [188]. Rafts also play
an important role in neuronal cell adhesion [193], local-
ization of neuronal ion channels [194, 195] and axon
guidance [196]. In oligodendrocytes, rafts mediate the
interaction between myelin associated glycoprotein on
myelin and its receptor on neurons [197].
Ceramide signaling in apoptosis
Apoptosis is an essential process for normal embryonic
development and to maintain cellular homeostasis within
mature tissues. A proper balance between regulation of
normal cell growth and cell death is the basis of life.
Deregulated apoptosis is a feature of most pathological
conditions such as neurodegeneration, auto immune disor-
ders and cancer. In neurodegenerative diseases such as
Alzheimer’s, Parkinson’s, Huntington’s and Prion’s diseases
aggregated misfolded proteins contribute to the neuronal
pathogenesis; in multiple sclerosis, autoimmune mechanisms
accompany the demyelination; in HIV-associated dementia,
viral products are crucial for neuronal demise. Factors
affecting neurodegeneration can differ, but these devastating
disorders are all characterized by a massive loss of specific
populations of neurons or damage to neuronal transmission.
Premature death of terminally differentiated cells such
as neurons and oligodendrocytes results in progressive and
irreversible functional deficits since these post mitotic cells
cannot be easily replaced [198]. The role of ceramide in
apoptosis is extensive and complex and despite intense
investigations remains controversial [199]. An increase of
ceramide levels leads to cell death [200, 201]; in contrast,
depletion of ceramide can reduce the progression of
apoptosis [202–204]. However, ceramide is indispensable
for proper function of the central nervous system (CNS)
[205–207]. Ceramide levels inside the cell determine its
dual role: protection and cell sustenance at low concen-
trations but death and threat when over produced. This
outlines the importance for cells to maintain a strict cera-
mide balance by a tight regulation of sphingolipid based
signaling networks.
Ceramide can induce apoptosis via different routes and
different intracellular organelles are the target of its action.
SM hydrolysis by neutral and/or acid SMases is known to
be a very important pathway for production of pro-apop-
totic ceramides [208]. However, the de novo synthesis
pathway has also been reported to be relevant in the gen-
eration of a signaling pool of ceramide leading to cellular
apoptosis [209–211]. These two pathways can induce
apoptosis independently or jointly (Fig. 5).
SM hydrolysis generates a rapid and transient increase
of ceramide and results in formation of ceramide-enriched
membrane platforms. In contrast, the ceramide de novo
pathway requires multiple enzymatic steps and it is
responsible for a slow but robust accumulation of ceramide
over a period of several hours.
SMase activation occurs in response to stimulation of
cell surface receptors of the tumor necrosis factor (TNF)
upon the binding with specific ligands such as TNF alpha,
TNF-related apoptosis-inducing ligand (TRAIL) and Fas
ligands.
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SM hydrolysis in response to TNF signals involves both
nSMase and aSMase but their activation occurs through
different mechanisms [212, 213]. The cytoplasmic tail of
the TNFR1 contains two distinct portions that differently
associate with nSMase or aSMase [214, 215]. Activation of
aSMase requires the C-terminal of the TNFR1 identified as
death domain (DD) [216]. DD associates with the adaptor
protein TRADD (TNF receptor 1-associated death domain)
that together with another cytoplasmic protein, termed
FADD/MORT-1 [217] induces activation of aSMase [218].
ASMase is normally present in the endosomal/lysosomal
compartment. However, upon phosphorylation by protein
kinase C, aSMase translocates from its intracellular loca-
tions to the plasma membrane where it reaches SM [219].
ASMase is reported to be functional at physiological pH
after translocation to the plasma membrane [220]. The
ceramide produced by aSMase activates the aspartyl pro-
tease cathepsin D [221] that can subsequently cleave the
pro-apoptotic Bcl-2 family member Bid. Activation of Bid
induces cytochrome c release from mitochondria [222] and
activation of caspase-9 and -3, leading to apoptotic cell
death by the intrinsic pathway [223].
Conversely, activation of nSMase requires a short motif
adjacent to the DD of TNFR1, called neutral sphingomye-
linase domain (NSD). The NSD binds an adaptor protein,
FAN (factor associated with nSMase) which couples nSM-
ase to TNFR1 [224]. The ceramide generated by nSMase
leads to the activation of ceramide-activated protein kinase
(CAPK) [14] and ceramide-activated protein phosphatases
(CAPPs) [225], direct downstream targets of ceramide.
CAPK, Ser/Thr protein kinase, is involved in the mitogen-
activated protein kinase (MAPK) cascades that induce the
extracellular-signal regulated kinases (ERK) activation.
ERK cascade leads to cell cycle arrest and cell death.
CAPPs, which comprise the serine threonine protein
phosphatases PP1 and PP2A [226], mediate the effect of
ceramide through dephosphorylation and inactivation of
several substrates, such as retinoblastoma gene product
(RB) [227], Bcl-2 and Akt [228] and through downregu-
lation of the transcription factors c-Myc [229] and c-Jun
[230].
Although aSMase and nSMase seem to induce death
receptor dependent and independent mediated apoptosis
through apparently separate mechanisms, both enzymes are
activated by the same stimuli, i.e. UV light [231], hypoxia
[232, 233], radiation [204, 234], TNF-related apoptosis-
inducing ligands [235] and the DNA-damaging drug
doxorubicin [236]. Disruption of rafts or prevention of
ceramide generation by inactivation of aSMase, renders
cells resistant to receptor clustering and apoptosis indicat-
ing that aSMase plays an important role in death receptor-
mediated apoptosis [2, 237, 238]. Accordingly, aSMase-
deficient mice are resistant to the induction of apoptosis by
CD95 [239] and TNF alpha signaling [240].
Selective activation of nSMase has been reported to
occur for some apoptotic stimuli as CD40 [241], ethanol
[242], free oxygen radicals [243] and chemotherapy drugs
[244] (Fig. 5). In contrast, specific activation of aSMase
with subsequent formation of ceramide-enriched mem-
brane domains occurs after infection with Pseudomonas
aeruginosa [245], Staphylococcus aureus [246] or rhino-
virus [247].
Instead, exposition to the chemotherapeutic agent eto-
poside [211] and cannabinoids [248], retinoic acid [249]
and B cell receptor (BcR)-induced apoptosis [250] all
involve a large increase in ceramide levels formed spe-
cifically through the de novo pathway. However, the
downstream targets of the de novo ceramide dependent cell
death are largely unknown.
In conclusion, evidence suggests that ceramide acts
either by changing the physical state and organization of
cellular membranes or by direct binding and activation of
target proteins. The spatial reorganization of plasma
membrane driven by generation of ceramide may serve
to cluster signaling molecules and to amplify death sig-
naling. However, rather than a specific mechanism for
apoptosis induction, this process appears to represent a
generic mechanism for transmembrane signaling. In fact,
receptors that are not involved in apoptosis (IL5, LFA 1,
CD28, CD20) [251] can activate the SMase signaling
pathway with subsequent raft clustering into micro-
domains. Beside its effect at the level of cellular mem-
branes, ceramide is capable of direct binding with
components that lead to death as CAPP, CAPK, protein
kinase C-n, cathepsin D [252] and mediate induction of
signaling cascades that lead to apoptosis, growth arrest
and inflammation.
Fig. 5 Ceramide production occurs in response to diverse apoptotic
stimuli and with different mechanisms. Many inducers of cell death
activate one or more ceramide generation pathways. For example both
SM hydrolysis (by either a nSMase or an aSMase) and the de novo
pathway have been implicated in the action TNFa, radiation,
doxorubicin and UV. Ultimately, ceramide production results in cell
death regardless of the pathway
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Aging
Sphingolipids hold a major role in regulating development
and lifespan [253] and deregulation in sphingolipid
metabolism increase the risk and progression of age-related
neurodegenerative disease [254, 255]. Since ceramide is
the core of sphingolipids, its contribution to cellular path-
ophysiology is object of intense study. A close connection
between ceramide levels and aging comes from studies
carried on Saccharomyces cerevisiae where a gene
involved in ceramide synthesis has been identified as a
regulator of yeast longevity. This gene called longevity
assurance homolog 1 (LAG1), together with LAC1, func-
tions as a key components of CerS in vivo and in vitro
[256] and its lost correlates with a marked increase in yeast
lifespan [257]. The human homolog LAG1Hs (CerS1) is
highly expressed in the brain, testis and skeletal muscles
and specifically generates C18-ceramide [46]. This con-
clusion seems to be supported by cell culture studies where
overexpression of CerS1 with increased C18-ceramide
generation resulted in apoptosis [258]. Interestingly, C18-
ceramide generated by CerS1 was found to downregulate
the expression of the enzyme telomerase [259]. Telomerase
functions by elongating the end of existing chromosomes
and thus preventing cellular senescence. Since cellular
aging is dependent on cell division, these enzymes play a
critical role in long-term viability of highly proliferative
organ systems [260]. Specifically C18-ceramide is able to
mediate a negative regulation of the human telomerase
reverse transcriptase (hTERT) promoter, whereas different
ceramides generated by other ceramide synthases do not
have such a function. Telomerase is expressed in neurons
in the brains of rodents during embryonic and early post-
natal development and is subsequently downregulated
[261]. Terminally differentiated neurons are postmitotic,
therefore there is not need to maintain the telomere length
[262]. However, telomerase is constitutively expressed in
restricted regions of the hippocampus and the olfactory
bulbs which are continuously supplied with neural stem
and progenitor cells [263]. These cells are required for
adult neurogenesis throughout life because they produce
new neurons and support brain cells. Therefore, besides the
telomeric roles, telomerase was found to protect the post-
mitotic neuronal cells from stress-induced apoptosis and
may serve a neuron survival-promoting function in the
developing brain and be important for regulating normal
brain functions. Thus, the regulation that C18-ceramide
seems to exert on telomerase expression may contribute to
increase neuronal vulnerability of the adult brain in various
age-related neurodegenerative disorders.
Several studies support the role of ceramide in inducing
senescence and in activating genetic/biochemical pathways
involved with aging. Accumulation of ceramide occurs
normally during development and aging in single cells
[264] and young cells treated with exogenous ceramide
exhibit a senescent-like phenotype [265].
In addition, a significant change in ceramide metabolic
enzyme activities seems to occur in specific organs or even
in specific cell types with aging [264, 266]. The activities
of the sphingolipid catabolic enzymes (SMase and CDase)
seem to change more robustly than that of the anabolic
enzymes (SMS and CerS).
ASMase and nSMase activity significantly increase in
rat brain during aging [267] demonstrating that aging is
accompanied by an increase in SM turnover. NSMase was
also reported to be dramatically activated in senescent
fibroblasts [264]. ACDase, nCDase and alCDase activities
are increased specifically in brain tissue from aging rats
and among the isoforms of CDases, alCDase shows the
highest activity [267]. Increase in the CDase activity in
kidney and brain indicates an increase in the production of
sphingosine and its contribution toward aging in these
tissues. In contrast, CerS shows a lower activity, suggesting




Ceramide is defined as a central element in the metabolic
pathways of sphingolipids. All sphingolipids are synthe-
sized from ceramides and are hydrolyzed to ceramides. In
addition to CDase and SMase, there are other hydrolytic
enzymes which hydrolyze complex sphingolipids produc-
ing ceramides as product. More than ten specific acid
exohydrolases are responsible for intracellular GSLs
digestion in a stepwise action that takes place within the
lysosome. Deficiency or malfunctioning of one of these
enzymes results in accumulation of the corresponding lipid
substrate in the lysosomal compartment leading to cellular
enlargement, dysfunction and death. Due to its high syn-
thesis of lipids, the brain is the organ mainly affected by
accumulation of lipid products. Their abnormal storage and
slow turnover results in severe dementia and mental
retardation. Inherited metabolic disorders which have
been linked to lysosomal dysfunction belong to a family
of diseases identified as lysosomal storage disorders
(LSDs).
LSDs include Farber’s disease, caused by the dysfunction
of aCDase; Krabbe’s disease (Globoid leukodystrophy),
caused by the absence of galactosylceramidase (GalCer/3-
galactosidase); Gaucher’s disease due to the absence of
glucosylceramidase (GlcCer/3-glucosidase) and Niemann–
Pick disease (NP) characterized by the absence of aSMase.
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Farber’s disease
Farber’s disease is an inherited disorder characterized by
high levels of ceramides due to deficient activity of lyso-
somal aCDase [268]. The rate of ceramide synthesis is
normal but ceramide resulting from degradation of complex
sphingolipids cannot be hydrolyzed and it is confined into
the lysosomal compartment [269]. There is a significant
correlation between the ceramide accumulated in situ and
the severity of Farber disease [270]. The abnormal ceramide
storage in the brain results in neuronal dysfunction, leading
to progressive neurologic deterioration. The inflammatory
component of this disease consists in chronic granuloma-
tous formations [271]. Granuloma are small areas
characterized by the presence of lymphocytes, monocites
and plasma cells [272] and appear to result from a dysreg-
ulation of leukocyte functions. However, the sequence of
molecular mechanisms leading from defect in ceramide
metabolism to leukocyte dysregulation is still unknown.
Krabbe’s disease and Gaucher’s disease
Krabbe’s disease is a disorder involving the white
matter of the central and peripheral nervous systems. It is
characterized by a deficiency in the lysosomal enzyme gal-
actosylceramidase which removes galactose from galacto-
ceramide derivatives. Galactosylceramidase is necessary to
digest galactosylceramide, a major lipid in myelin forming
oligodendrocytes and Schwann cells [273]. Abnormal stor-
age of galactosylceramide due to the lack of this enzyme
leads apoptosis of myelin forming cells with a complete
arrest of the myelin formation and consequent axonal
degeneration. This accounts for the severe degeneration of
motor skills observed in the disease. Another GSL called
psychosine (the deacylated form of galactosylceramide, also
known as galactosylsphingosine) is normally broken down
by galactosylceramidase. Psychosine is present in the normal
brain tissues at very low concentrations, owing to its rapid
breakdown to sphingosine and galactose by galactosylce-
ramidase. In its absence, psychosine accumulates in the brain
acting as cytotoxic metabolite [274] and therefore contrib-
uting to oligodendroglial cell death. Psychosine was also
found to cause axonal degeneration in both the central and
peripheral nervous system by disrupting lipid rafts [275].
Myelin and/or oligodendrocyte debris produced by oligo-
dendrocyte death in Krabbe’s disease activates microglial
cells, resident macrophages in the brain, which are the pri-
mary mediators of neuroinflammation [276]. Because a
pathological hallmark of this rapidly progressive demyelin-
ating disease is the presence of multinucleated macrophages
(globoid cells) in the nervous system [277] the disease is also
known as globoid cell leukodystrophy. However, the func-
tion of these cells is unclear.
Gaucher’s disease is characterized by the lysosomal
accumulation of GlcCer due to defects in the gene encoding
the lysosomal hydrolase glucosylceramidase [278]. In the
brain, GlcCer accumulates due to the turnover of complex
lipids during brain development [279]. The cells most
severely affected are neurons because they process large
amounts of gangliosides which are components of their
membranes and synapses. The demyelination or disrupt of
the membrane structure may be the major consequence of
these diseases and it is conceivable that a change in the
ceramide at the plasma membrane level may contribute to
these disorders. Enzymes involved in ganglioside degrada-
tion are highly expressed in brain tissue and are of particular
importance in the first few years of life when axons elongate,
dendrites branch and synapses develop [279]. Deficiency of
these enzymes causes neuronal storage of gangliosides
leading to loss of neurons and their axons, resulting in cor-
tical atrophy and white matter degeneration. Cells and
organs that do not process large amounts of gangliosides are
either normal or show mild storage without cell damage.
Niemann Pick’s disease
Defects in SM degradation results in a neurodegenerative
condition known as NP. This kind of disorder exists in three
major forms. Both NP type A and type B are caused by defects
in lysosomal aSMase activity. Affected individuals cannot
convert SM to ceramide [280] and alteration of the ceramide–
SM ratio, rather than SM accumulation, is likely responsible
for the onset of the disease. The importance of SM as a source
of ceramide is indicated by the fact that activation of the
aSMAase occurs in response to numerous signals within the
cell and the production of ceramide is critical for an appro-
priate signaling cascade. NP type C diseases are caused by
defects in a protein, NP C1 protein, which is located in
membranes inside the cell and is involved in the movement of
cholesterol and lipids within cells [281]. A deficiency of this
protein leads to the abnormal accumulation of cholesterol and
glycolipids in lysosomes and leads to relative deficiency of
this molecule for steroid hormones synthesis.
Neurodegenerative dementia: Alzheimer’, Parkinson’
and Prion’s diseases
Neural cells are very complex morphologically. The large
plasma membrane surfaces of neurons are important for
neuronal trafficking, neuron–neuron communication and
signaling transduction. During aging and neurodegenera-
tion membrane dysregulation and dysfunction are often
found. These alterations in membrane microenvironment
occur very early in the CNS [282, 283]. Heightened oxi-
dative stress has a profound impact upon membrane lipid-
protein organization and signal transduction [284]. These
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changes might be at the basis of diseases such as Alzhei-
mer’s disease, Parkinson’s disease (PD), synucleinopathies,
prion diseases, and other dementias.
Lipid rafts have been shown to be involved in the reg-
ulation of APP processing and in Ab peptide formation
[285], and represent the principal sites within the mem-
brane where b-secretase and c-secretase generate the
pathological amyloid b peptide [286–290].
Other lipid raft components, such as the gangliosides
GM1 and GM2, have been associated with induction of Ab
transition from a a-helix-rich structure to a b-sheet-rich
conformation [291, 292]. Ganglioside binding with Ab
accelerates Ab fibril formation [293] which gradually causes
membrane raft disruptions and thereby has profound con-
sequences on signal transduction and neurotransmission.
Prion protein (PrPc) is a GPI-anchored protein [294] and
together with its pathological variant associates with lipid
rafts [295]. Moreover, the conversion of PrPc into PrPSc has
been shown to occur in these membrane domains [296].
Alpha-synuclein associates specifically with lipid rafts [297]
and abnormalities of lipid rafts in the frontal cortex occur
during the development of PD pathology [298]. Massive
modification of fatty acid content gives rise to more viscous
and liquid ordered rafts in PD brains than in the age-matched
control group [298]. Also, lipid rafts from AD brains exhibit
aberrant lipid profiles compared to healthy brains [299].
Similar lipid changes are also observed in epilepsy and
ischemia/stroke [300, 301]. Elevations of intracellular
ceramide levels, which may in turn be associated with
induction of apoptotic cell death, have been reported in
brain tissues and CSF of AD brain [302] together with
reduced SM [303] and altered ganglioside levels [304]. In
line with this, an increase of aCDase [305] and aSMase
activity [306] has been detected in the brain of AD patients.
The key enzyme in ceramide de novo synthesis, SPT, is
regulated by APP processing [307] suggesting that this
could be one of probably many mechanisms responsible for
the alterations in lipid metabolism at the plasma membrane.
Conclusions
Ceramide is an important signaling molecule involved in
the regulation of cell development, growth and apoptosis.
In healthy cells ceramide metabolism is finely tuned and
precisely coordinated and the level of ceramide generated
can dictate whether development is stimulated or whether
apoptosis is induced. Ceramide is beneficial for early
growth and development of neuronal cells [308, 309] and at
low levels it has trophic effects promoting cell survival and
division. Initial abnormal formation of ceramide can
potently induce more ceramide accumulation in a self-
sustaining way [200, 310] that results to be toxic and
supports pro-apoptotic actions in many cell types [311].
This induces drastic consequences leading to tissue damage
and organ failure [312]. The mechanisms by which cera-
mide induces these disparate effects is not known, but may
involve its effects in membrane structure and/or activation
of different downstream signaling pathways.
These apparently contradictory roles can be understood
only when we consider ceramide formation as a balanced
and vulnerable system. This is, however, a fine line to tread
and deviation in either direction can have drastic conse-
quences. Where ceramide is concerned, growth arrest or
apoptosis are only a slight tilt away.
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